Amantadine intoxication despite moderate renal dysfunction: A case of combined use with donepezil

Kouji Okada1,2 | Takashi Uno2 | Miho Utsumi2 | Kensuke Usui1,2 | Masashi Nakamura3 | Ichiro Nakashima3 | Eiji Suzuki4 | Yoshiteru Watanabe1,2

1Department of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, Sendai, Japan
2Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
3Division of Neurology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
4Division of Psychiatry, Tohoku Medical and Pharmaceutical University, Sendai, Japan

Abstract
Amantadine intoxication occurred despite moderate renal dysfunction. This may have been affected by the use of donepezil, and we require careful attention to these combinations.

KEYWORDS
amantadine, cerebral infarction, donepezil, intoxication, involuntary movement, moderate renal dysfunction

1 | INTRODUCTION

Administration of amantadine and donepezil to improve patient with Alzheimer-type dementia and cerebral infarction led to involuntary movements. Amantadine blood concentration reached a toxic level (3647 ng/mL). It is necessary to carefully monitor patients with even moderate renal dysfunction, who receive combinations of amantadine and drugs, such as donepezil.

Amantadine acts on dopaminergic neurons and is used to treat symptoms of Parkinson's disease.1 This drug also alleviates the decrease in spontaneity due to late effects of cerebral infarction,2 and it is approved for this purpose in Japan. As elimination is primarily achieved through renal clearance, half-life of amantadine is longer in patients with renal dysfunction.3 The renal clearance of amantadine can exceed creatinine clearance (Ccr), suggesting that tubular secretion can play a role in elimination. Hence, amantadine doses must be reduced in patients with renal dysfunction to avoid toxicity.4 So far, amantadine intoxication has only been reported in patients with renal failure.5,7 However, the aim of this study is to report our clinical experience with a patient who developed toxic symptoms due to an increase in blood amantadine concentration during the combined use of donepezil, while being diagnosed with cerebral infarction and moderate renal dysfunction.

2 | CASE HISTORY

The patient was an 80-year-old woman. Her medical history consisted of arrhythmia that had developed 16 years ago, Alzheimer's disease 4 years ago, and a fracture in the
right femoral neck 2 years ago. Due to motor aphasia and right hemiparesis, she was admitted to our hospital and diagnosed with cerebral infarction. Findings upon admission included height 152.0 cm, weight 52.2 kg, blood pressure 149/59 mm Hg, pulse 89 beats per minute, temperature 36.5°C, and SpO₂ 93%-95% (room air). Medicines that were brought were canceled on admission.

The time course of drug administration and symptoms are illustrated in Figure 1, and the transition of laboratory values and vital signs are summarized in Table 1. On the day after hospitalization, the patient received heparin sodium, edaravone, and fluid replacements. On the 13th day, right hemiparesis was still persistent. In addition to hemiparesis, her decreased spontaneity due to the late effects of cerebral infarction diminished her oral intake. Therefore, she received simultaneous administration of amantadine (150 mg/d for the loss of spontaneity with the late effects of cerebral infarction) and apixaban via a nasogastric tube. Furthermore, because there was not much improvement in her spontaneity and mobility due to Alzheimer’s dementia, 3 mg/d of donepezil was administered on the 16th day, followed by 5 mg/d donepezil on the 24th day. On the 27th day, involuntary movements (stiffening and tremor) started appearing. On the 30th day, tremors were observed across the entire body when the patient was being addressed or touched, which were presumed to be Gegenhalten. We also suspected that the tremors were extrapyramidal symptoms and, hence, stopped the administration of donepezil. On the 34th day, involuntary movements (stiffening and tremor) started to appear. On the 37th day, clonazepam was initiated due to the persistence of myoclonus-like involuntary movement. On the 40th day, both stimulated systemic hypertonia and involuntary movement seemed to improve. On the 49th day, the toxic symptoms disappeared and the patient was discharged from the hospital.

3 | DISCUSSION

We experienced a case of amantadine intoxication despite the presence of only moderate renal dysfunction. Previous reports indicate that toxic symptoms are observed if amantadine blood concentration exceeds 3000 ng/mL. In our case, we found that amantadine had reached toxic levels. We suspect that individual differences in the ability to excrete the drug and/or the effects of combined use of donepezil caused amantadine intoxication in this case.

Nishikawa et al (2009) also reported that plasma amantadine concentration exhibited a significant negative correlation with Ccr. And a 4-fold range in blood concentration was noted when 100 mg/d of amantadine was administered to patients with normal renal function. The dosage of amantadine in the package insert for the late effect of cerebral infarction was “100-150 mg/d divided into 2-3 doses.” The dosage of amantadine was within the standard dose range; however, it may have been an overdose for our patient. Other reports also describe the use of amantadine intoxication to improve the spontaneity of patients with moderate renal dysfunction. As most of amantadine is excreted into urine in the unchanged form, individual differences in the ability to excrete the drug concentration of amantadine was measured, which was found to be at a toxic level (3647 ng/mL). Creatine kinase was within the normal range, and no malignant syndromes were found. On the 37th day, clonazepam was initiated due to the persistence of the myoclonus-like involuntary movement. On the 40th day, both stimulated systemic hypertonia and involuntary movement seemed to improve. On the 49th day, the toxic symptoms disappeared and the patient was discharged from the hospital.
are the cause of fluctuation in the blood amantadine levels. A report described how amantadine intoxication at 150 mg/d in a patient with moderate renal dysfunction could be controlled by the re-administration of amantadine at 50 mg/d initially and then gradually increasing the dosage.9

The potency of the drug interaction between amantadine and donepezil should be studied, as amantadine intoxication symptoms were found to occur while using donepezil. Donepezil is effective in reducing involuntary movements due to Alzheimer's dementia,10 which was also observed in this case. Amantadine is known as a drug having a large ratio of tubular secretion to the renal clearance (from the information in the package insert). Memantine, an N-methyl-D-aspartate receptor inhibitor with a structure similar to amantadine, is a substrate of the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion protein 1 (MATE1).11 OCT2 is primarily a renal uptake transporter that is expressed on the basolateral (blood) side of the proximal tubule cells. MATE1 is an apically expressed poly-specific proton antiporter that mediates renal efflux of diverse substrates that are primarily organic cations. Donepezil inhibits both OCT212 and MATE1.13 We hypothesize that the combined use of amantadine and donepezil led to competition in transport of amantadine through OCT2 and MATE1 leading to inhibition of its excretion and a consequent increase in its blood concentration. Although pharmacokinetics data are not available for the combination of amantadine and donepezil, there are several reports on memantine, which has a structure and activity similar to those of amantadine. An in vivo study reported that the combination of donepezil and memantine decreased clearance of memantine and hence increased its blood concentration and its area under the curve.14 However, no significant pharmacokinetic interaction was observed in a co-administration study of donepezil and memantine conducted on healthy human subjects.15 Moreover, meta-analyses have also investigated the combined efficacy and safety of donepezil and memantine for Alzheimer-type dementia.16 Currently, the effect of the combination of memantine and donepezil is not considered a clinical problem. However, to the best of our knowledge, there are no reports on the direct evaluation of the effects of the combination of amantadine and donepezil. Drug interactions related to renal transporters

### Table 1
Summary of laboratory values and vital signs from day 1-day 47, where “day” refers to time after hospitalization

| Laboratory data | Day 1 | Day 13 | Day 27 | Day 36 | Day 47 |
|-----------------|-------|--------|--------|--------|--------|
| WBC ×10^3/µL    | 5.8   | 4.6    | 5.1    | 7.8    | 4.4    |
| Hgb g/dL        | 15.3  | 13.9   | 13.1   | 11.7   | 12.2   |
| PLT ×10^3/µL    | 16.2  | 29.1   | 27.8   | 24.4   | 38.2   |
| AST U/L         | 12    | 9      | 20     | 16     | 17     |
| ALT U/L         | 4     | 5      | 40     | 22     | 23     |
| LDH U/L         | 150   | 210    | 256    | 235    | 218    |
| CK U/L          | 15    | –      | –      | 47     | –      |
| Scr mg/dL       | 0.81  | 0.61   | 0.65   | 0.65   | 0.56   |
| BUN mg/dL       | 13    | 21     | 20     | 30     | 20     |
| Ccr mL/min      | 43    | 58     | 54     | 54     | 63     |
| Alb g/dL        | 3.9   | 2.9    | 3.1    | 3.2    | 2.6    |
| Na mEq/L        | 137   | –      | 132    | 132    | 138    |
| K mEq/L         | 4.6   | –      | 4.5    | 4.0    | 4.5    |
| Cl mEq/L        | 100   | –      | 96     | 96     | 105    |
| CRP mg/dL       | 0.03  | 1.47   | 0.93   | 1.65   | 1.22   |

| Vital sign | | | | | |
|------------| | | | | |
| SpO2 %     | 93-98 | 95 | 98 | 85-96 | 96-97 |
| PR bpm     | 89-105 | 85-90 | 55 | 110-133 | 100 |
| SBP mm Hg  | 132-149 | 114-136 | 118 | 128-130 | 125 |
| DBP mm Hg  | 59-88 | 60-73 | 64 | 66-84 | 68 |

Note: “day” means days of after hospitalization.

Abbreviations: Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Ccr, creatinine clearance; CK, creatine kinase; Cl, serum chloride; CRP, C-reactive protein; DBP, diastolic blood pressure; Hgb, haemoglobin; K, serum potassium; LDH, lactate dehydrogenase; Na, serum sodium; PLT, platelet count; PR, pulse rate; SBP, systolic blood pressure; Scr, serum creatinine; SpO2, blood oxygen saturation; WBC, white blood cell count.
are becoming clear, but there are many obscurity points. And these drug interactions are still not well recognized in clinical practice.\textsuperscript{17} In fact, the package insert does not contain any information about drug interactions between amantadine and donepezil. In this report, we presume amantadine intoxication because of their interaction through renal transporter inhibition although the mode of action will need further investigation.

4 \hspace{1pt} CONCLUSIONS

Amantadine is excreted renally at a high rate in the form of the unchanged drug. In this case, amantadine concentrations in the blood increased to toxic levels despite moderate renal dysfunction. It is necessary to carefully monitor the patient for toxic symptoms caused by amantadine, especially in patients receiving a combination of amantadine and drugs such as donepezil.

ACKNOWLEDGMENTS

The authors thank Dr M. Nagai (Ehime University, School of Medicine Hospital) for his technical assistance in determining the concentration of amantadine in the blood.

CONFLICT OF INTEREST

We declare no conflict of interest.

AUTHOR CONTRIBUTIONS

KO: designed the study, analyzed and interpretation of data, and wrote the manuscript. TU and MU: provided pharmacutical care to patient, collected data, and were involved in manuscript drafting and editing. KU: contributed to case investigation. MN and IN: provided clinical care to patient and were involved in manuscript drafting and editing. ES and YW: were involved in manuscript drafting and editing. KU: contributed to case investigation. MN and IN: provided clinical care to patient, collected data, and were involved in manuscript drafting and editing. ES and YW: were involved in manuscript drafting and editing. KU: contributed to case investigation.

ORCID

Kouji Okada \hspace{1pt} https://orcid.org/0000-0001-7191-2857

REFERENCES

1. Schwab RS, England Jr AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:1168-1170.
2. Yamada K, Tanabe H, Yoshino K, et al. Clinical effect of Symmetrel for decreased willingness and spontaneity resulting from cerebral infarction. J Med. 1990;24:853-869.
3. Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med. 1981;94:454-458.
4. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol. 1982;17:19-23.
5. Strong DK, Eisenstat DD, Bryson SM, Sitar DS, Arbus GS. Amantadine neurotoxicity in a pediatric patient with renal insufficiency. Dicp. 1991;25:1175-1177.
6. Macchio GJ, Ito V, Sahgal V. Amantadine-induced coma. Arch Phys Med Rehabil. 1993;74:1119-1120.
7. Nakata M, Ito S, Shirai W, Hattori T. Severe reversible neurological complications following amantadine treatment in three elderly patients with renal insufficiency. Eur Neurol. 2006;56:59-61.
8. Nishikawa N, Nagai M, Moritoyo T, Yabe H, Nomoto M. Plasma amantadine concentrations in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:351-353.
9. Kunieda K, Shigematsu T, Fujimasa I. Case reports describing amantadine intoxication in a rehabilitation hospital. Prog Rehabil Med. 2017;2:20170017.
10. Gauthier S, Feldman H, Hecker J, et al. Emir B; Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002;14:389-404.
11. Müller F, Weitz D, Derdua V, et al. Contribution of MATE1 to renal secretion of the NMDA receptor antagonist memantine. Mol Pharm. 2017;14:2991-2998.
12. Hacker K, Maas R, Kornhuber J, Fromm MF, Zolk O. Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates. PLoS ONE. 2015;10:e0136451.
13. Martínez-Guerrero LJ, Morales M, Ekins S, Wright SH. Lack of influence of substrate on ligand interaction with the human multidrug and toxin extruder, MATE1. Mol Pharmacol. 2016;90:254-264.
14. Hassan MG, Ikeda R, Wada M, et al. Interaction study of acetylcholinesterase inhibitors on pharmacokinetics of memantine in rat plasma by HPLC-fluorescence method. Biomed Chromatogr. 2013;27:1685-1689.
15. Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother. 2004;38:1389-1394.
16. Chen R, Chan PT, Chu H, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis. PLoS ONE. 2017;12:e0183586.
17. Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56:825-892.